{"transactions":[{"id":909680,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":272056,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":272056},"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909679,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":222591,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":222591},"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909678,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":767294,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":767294},"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909677,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1150941,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1150941},"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909676,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":767294,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":767294},"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909675,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1150941,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1150941},"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909674,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":248034,"price":16,"value":3968544.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":2054678,"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909673,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":3441966,"price":16,"value":55071456.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":5966439,"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909672,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1806644,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":1806644,"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909671,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T22:15:24.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":2524473,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":2524473,"source":{"system":"sec-edgar","filing":"0001231919-26-000135","document":"form4-02112026_100217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000135/form4-02112026_100217.xml","form_type":"4"}},{"id":909596,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":359255,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359255},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":909595,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":548067,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":909594,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":548067,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548067},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":909593,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":41682,"kind":"person","name":"Nielsen Kirk G.","position":1,"cik":"0001523522","reported_name":"Nielsen Kirk G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T22:13:35.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1690230,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Vensana Capital I, L.P. (\"Vensana I\"). Vensana Capital I GP, LLC (\"Vensana GP I\") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the \"GP I Managing Directors\") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1690230},"source":{"system":"sec-edgar","filing":"0001193125-26-046833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1523522/000119312526046833/ownership.xml","form_type":"4/A","original_submission_date":"2026-02-10"}},{"id":909524,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909523,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909522,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909521,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909520,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909519,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909518,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909517,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909516,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909515,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909514,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909513,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909512,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909556,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909555,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909554,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909553,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909552,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909551,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909550,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909549,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909548,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909547,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909546,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909545,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909544,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:21.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526046674/ownership.xml","form_type":"4"}},{"id":909498,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909497,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909496,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909495,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909494,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909493,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909492,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909491,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909490,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909489,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909488,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909487,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909486,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:10.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630226/000119312526046668/ownership.xml","form_type":"4"}},{"id":909761,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909760,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909759,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909758,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909757,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909756,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909755,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909754,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909753,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909752,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909751,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909750,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909749,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:08.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526046666/ownership.xml","form_type":"4"}},{"id":909461,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909460,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909459,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909458,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909457,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909456,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909455,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909454,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909453,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909452,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909451,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909450,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909449,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:06.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746342/000119312526046663/ownership.xml","form_type":"4"}},{"id":909636,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909635,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909634,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909633,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909632,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909631,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909630,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909629,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909628,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:04.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526046664/ownership.xml","form_type":"4"}},{"id":909359,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":66852,"kind":"person","name":"Khan Bilal Arshad","position":1,"cik":"0002108044","reported_name":"Khan Bilal Arshad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:07:19.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":115000,"price":16,"value":1840000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical.  The Reporting Person disclaims beneficial ownership of such shares, except to the extent of their pecuniary interest in the shares."}],"balance_after":251427,"source":{"system":"sec-edgar","filing":"0002108044-26-000006","document":"form4-02112026_090215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1778922/000210804426000006/form4-02112026_090215.xml","form_type":"4"}},{"id":909358,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":66852,"kind":"person","name":"Khan Bilal Arshad","position":1,"cik":"0002108044","reported_name":"Khan Bilal Arshad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:07:19.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":16,"value":320000.0,"ownership":{"direct":true},"balance_after":25450,"source":{"system":"sec-edgar","filing":"0002108044-26-000006","document":"form4-02112026_090215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1778922/000210804426000006/form4-02112026_090215.xml","form_type":"4"}},{"id":909693,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909692,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909691,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909690,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909689,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909688,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909687,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909686,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909685,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}},{"id":909684,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:19.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046673","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526046673/ownership.xml","form_type":"4"}}],"next_cursor":"2026-02-11T16:30:19.000000Z,909684"}